Menter, Alan, Andrew Blauvelt, Bruce Strober, Matthew Colombo, Renata Kisa, Sudeep Kundu, Subhashis Banerjee, and Craig Leonardi. 2020. “Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis”. SKIN The Journal of Cutaneous Medicine 4 (6):s72. https://doi.org/10.25251/skin.4.supp.72.